Zhiwei Yao, Yu Xiao, Wen Li, Shuhui Kong, Hailong Tu, Siwei Guo, Ziyi Liu, Lushun Ma, Ruifeng Qiao, Song Wang, Miao Chang, Xiaoxu Zhao, Yuan Zhang, Lei Xu, Daqing Sun, Xiaolong Fu
PURPOSE: Cisplatin is a low-cost clinical anti-tumor drug widely used to treat solid tumors. However, its use could damage cochlear hair cells, leading to irreversible hearing loss. Currently, there appears one drug approved in clinic only used for reducing ototoxicity associated with cisplatin in pediatric patients, which needs to further explore other candidate drugs. METHODS: Here, by screening 1967 FDA-approved drugs to protect cochlear hair cell line (HEI-OC1) from cisplatin damage, we found that Tedizolid Phosphate (Ted), a drug indicated for the treatment of acute infections, had the best protective effect...
April 15, 2024: Journal of the Association for Research in Otolaryngology: JARO